Off-label use of rituximab for systemic lupus erythematosus in Europe

scientific article

Off-label use of rituximab for systemic lupus erythematosus in Europe is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1136/LUPUS-2016-000163
P932PMC publication ID5013507
P698PubMed publication ID27651920

P50authorGuillermo Ruiz-IrastorzaQ37830875
Andrea DoriaQ38544117
David A. IsenbergQ42326409
Gabriella SzűcsQ91312009
Xavier MarietteQ93104907
Manuel Ramos-casalsQ42646201
Ronald van VollenhovenQ47265013
Elisa GremeseQ50166371
Tom HuizingaQ77086497
P2093author name stringThomas Dörner
Ola Nived
Cristina Gonzalez-Echavarri
Marta Mosca
Murat Inanç
Søren Jacobsen
Joaquim Oristrell
Antoni Castro
Monica Rydén-Aulin
Gian Domenico Sebastiani
Dimitrios Boumpas
Jose Luis Callejas Rubio
Luis Caminal-Montero
Annamaria Iuliano
Luis Sáez-Comet
Lászlo Kovács
Danilo Squatrito
Frederic A Houssiau
Alexandre Voskuyl
Javier Rascón
Agustín Colodro Ruiz
Gonzalo Salvador Cervelló
Irene Bultink
Juan Jimenéz-Alonso
P2860cites workA phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusQ28254310
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialQ28304807
Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry.Q30967810
Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients.Q33491307
The prevalence of rheumatic diseases in central Greece: a population surveyQ33588016
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseasesQ34369159
Rituximab versus cyclophosphamide for ANCA-associated vasculitisQ35109118
British Society for Rheumatology Biologics RegisterQ35579314
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trialQ35993027
Rheumatoid arthritis registries in Sweden.Q36307644
Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapyQ36518986
Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcomeQ37123206
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.Q38205079
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab studyQ38466691
Epidemiology of systemic lupus erythematosus in northwest Greece 1982-2001.Q39645963
Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapyQ40331569
The prevalences of some rheumatic diseases in western Turkey: Havsa studyQ40337416
Prolonged remission in Caucasian patients with SLE: prevalence and outcomesQ41533364
Lupus in Germany: analysis within the German lupus self-help organization (LULA)Q41912513
Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritisQ80060133
B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximabQ80502406
Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two casesQ81963943
Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER)Q83817360
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitisQ42963758
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.Q43472878
An open study of B lymphocyte depletion in systemic lupus erythematosusQ44183280
Systemic lupus erythematosus in the community. Incidence, prevalence, outcome, and first symptoms; the high prevalence in black womenQ44531096
Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortalityQ44795825
The prevalence of systemic lupus erythematosus in Northern IrelandQ44940491
Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?Q45991822
Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective studyQ46140763
Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological featuresQ47329844
An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of lifeQ48435382
DANBIO: a nationwide registry of biological therapies in Denmark.Q50542827
Systemic lupus erythematosus in Denmark: clinical and epidemiological characterization of a county-based cohort.Q50561696
Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis.Q50658322
Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID).Q51201612
The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus.Q51967849
Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of responseQ57349317
The prevalence and incidence of systemic lupus erythematosus in Nottingham, UK, 1989-1990Q60704939
Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapyQ61628464
The prevalence of diagnosed systemic lupus erythematosus in whites and Indian Asian immigrants in Leicester city, UKQ67551750
The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birthQ72158504
P433issue1
P921main subjectsystemic lupus erythematosusQ1485
rituximabQ412323
P304page(s)e000163
P577publication date2016-09-06
P1433published inLupus science & medicineQ27725658
P1476titleOff-label use of rituximab for systemic lupus erythematosus in Europe
P478volume3

Reverse relations

cites work (P2860)
Q47660691B Cell-Based Treatments in SLE: Past Experience and Current Directions
Q92987312B cell checkpoints in autoimmune rheumatic diseases
Q40042816Characterization of patients with systemic lupus erythematosus who meet the diagnostic criteria for TAFRO syndrome
Q42373160Current perspective on rituximab in rheumatic diseases
Q64065293Immunosuppressive therapy with rituximab in common variable immunodeficiency
Q92540366Machine learning applied to whole-blood RNA-sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus
Q92625516Novel paradigms in systemic lupus erythematosus
Q92481861Rituximab utilization for approved and off-label nononcology indications and patients' experiences with the Patient Alert Card
Q33811635Systemic lupus erythematosus: Extent and patterns of off-label use of rituximab for SLE.
Q33665611The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
Q42372842Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
Q90614367[Biologicals and small molecules for systemic lupus erythematosus]
Q89894663[Tapering and termination of immunosuppressive therapy : Systemic lupus erythematosus]

Search more.